Filter posts

Picks and Pans – The Buy-Side View for 2012

What’s the forecast for biotech in 2012? Do investors think it is a good time …

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO …

Managing in a Cost-Constrained Environment

By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at …

Governor Chris Christie Will Headline BioNJ 2012 Annual Meeting

BioNJ, the trade association for New Jersey’s biotechnology industry, will welcome New Jersey Governor Chris …

Where's the Deal?

With only two weeks to go in 2011 it is looking like a five year …

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

The latest IPO window has stalled. There have been five IPO withdrawals since June and …

Perspective on Market Valuation for Biotech Drug Developers

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% …

Biotech IPO Window - Still Ajar?

IPO plans for Quark Pharmaceuticals were officially put on hold last week as markets continue …

Biotechnology Industry Initiative to Improve U.S. Science Education

By Bianca Blanks, Biotechnology Institute Industry responds to President’s “Educate to Innovate” campaign with “Scientists …

The Burrill Report: Pushing Policies in a Changed Washington

The Burrill Report’s Daniel Levine talks to BIO’s Alan Eisenberg regarding recent fluctuations in the …